976 Total HCV core antigen correlates with HCV RNA, and predicts response to PEGinterferon alfa 2-A (PEG-IFN) and ribavirin (RIB) therapy in chronic hepatitis C

Hepatology ◽  
2003 ◽  
Vol 38 ◽  
pp. 626-626
Author(s):  
E PADILLA ◽  
R PLANAS ◽  
V GONZALEZ ◽  
C PEREZ ◽  
D GIMENEZ ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Core Antigen ◽  
Hcv Rna ◽  
Hcv Core Antigen ◽  
Peginterferon Alfa

Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C

2013 ◽  
Vol 56 (3) ◽  
pp. 291-295 ◽  
Author(s):  
Elisabetta Loggi ◽  
Carmela Cursaro ◽  
Alessandra Scuteri ◽  
Elena Grandini ◽  
Arianna Martello Panno ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Standard Treatment ◽  
Core Antigen ◽  
Hcv Rna ◽  
Hcv Core Antigen

scholarly journals Serum HCV core antigen level is a useful prediction marker of serum HCV RNA negative at 24-week-treatment with peginterferon and ribavirin in patients with chronic hepatitis C

Kanzo ◽  
2006 ◽  
Vol 47 (8) ◽  
pp. 411-412
Author(s):  
Satoshi Shakado ◽  
Takashi Tanaka ◽  
Shinjiro Inomata ◽  
Akira Anan ◽  
Teruo Matsumoto ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Core Antigen ◽  
Hcv Rna ◽  
Antigen Level ◽  
Hcv Core Antigen ◽  
Peginterferon And Ribavirin

scholarly journals Quantification of Core Antigen Monitors Efficacy of Combination Therapy of Sofosbuvir, Daclatasvir and Ribavirin in Egyptian Cirrhotic Patients with HCV Infection as an Alternative to PCR

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
E H Nashaat ◽  
H Abdel-azziz ◽  
A I Mohammed ◽  
A H Hassan
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Hcv Infection ◽  
Core Antigen ◽  
Hcv Rna ◽  
Major Public Health Problem ◽  
Hcv Core Antigen ◽  
Cirrhotic Patients

Abstract Background Hepatitis C virus (HCV) is a major public health problem throughout the world. Acute HCV infection is asymptomatic in most cases, and only 15% of cases are symptomatic,but Chronic hepatitis C (CHC) shows a variable clinical course, ranging from mild histopathological changes to active hepatitis and the development of hepatic fibrosis, cirrhosis and HCC. The aim of this work is to detect accuracy of core antigen in Egyptian cirrhotic patients with HCV Infection treated with combination therapy of Sofosbuvir, Daclatasvir and Ribavirin as an alternative to PCR. Patients and methods: The study included20 Egyptian treatment-naïve chronic hepatitis C patients with cirrhosis (Cirrhosis was diagnosed on ultrasound basis) on Sofosbuvir, Daclatasvir and Ribavirin. Results Treatment with sofosbuvir plus Daclatasvir and Ribavirin for 12 weeks resulted in undetectable HCV RNA by PCR in 95% (19/20) of the patients at the end of treatment and only 5% (1/20) of the patients achieved SVR after 6 months not 3(both HCV RNA AND HCV Core Antigen tests were negative for all patients). Conclusion: In our study there was a correlation between HCV RNA and HCV core antigen results, so HCV core antigen can be used as an alternative marker to HCV RNA in treatment of HCV infected cirrhotic patients receiving Sofosbuvir, Daclatasvir and Ribavirin.during treatment and for monitoring its efficacy.

scholarly journals A Follow-up Study for Chinese Chronic Hepatitis C Patients Treated with the Combination of PEG-IFNα-2a (PEGASYS) and Ribavirin

2014 ◽  
Vol 3 (3) ◽  
pp. 103-107
Author(s):  
Zhu Chen ◽  
Yi-lan Zeng ◽  
Li Wang ◽  
Rong Hu ◽  
Yan Wang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Adverse Events ◽  
Chronic Hepatitis C ◽  
Virologic Response ◽  
Interferon Alfa ◽  
Hcv Rna ◽  
Peginterferon Alfa ◽  
To Receive

Abstract Objective To compare the efficacy of peginterferon alfa-2a (PEGASYS) plus ribavirin (RBV) with interferon alfa-2a plus RBV, and evaluate the safety. Methods Total of 117 patients with chronic hepatitis C were enrolled to receive either PEGASYS (135 μg or 180 μg) subcutaneously once per week, plus RBV (800 mg-1 200 mg) per day for 48 weeks (79 patients, PEGASYS group), or 5 million units of interferon alfa-2a subcutaneously every other day, plus RBV as above dosage for 48 weeks (38 patients, IFNα group). Results Sixty-three of 79 (79.7%) patients reached sustained virological response (SVR) in PEGASYS group, while 14 of 38 (36.8%) patients reached SVR in IFNα group. PEGASYS group was associated with a higher rate of virologic response than IFNα group at week 4, 12, 36, 48 and week 72. Sustained normalization of serum ALT concentrations at week 36, 48 and week 72 was also more common in PEGASYS group than in IFNα group. Baseline levels of ALT and HCV RNA had no effect on SVR in either PEGASYS group or IFNα group. Both groups were similar in the frequency and severity of adverse events. Conclusions PEGASYS plus RBV produced similar adverse events but higher rate of SVR. Meanwhile, complications should be prevented and treated promptly in order to increase compliances and effects.

Sign in / Sign up

Export Citation Format

Share Document